-+ 0.00%
-+ 0.00%
-+ 0.00%

Addex Therapeutics Reported Q3 EPS Of CHF(0.02) Up From CHF(0.03), Cash Balance Of CHF3.35M

Benzinga·11/22/2024 06:14:33
Listen to the news

Q3 2024 Operating Highlights:

  • Successfully completed funded research phase of the Indivior collaboration with both Indivior and Addex each selecting GABAB PAM drug candidate for further development in SUD and chronic cough, respectively
  • Completed Q3 2024 with cash and cash equivalents of CHF3.3 million